Reflex mechanisms responsible for early spontaneous termination of paroxysmal supraventricular tachycardia.
The incidence and possible mechanism of early spontaneous termination of paroxysmal supraventricular tachycardia was studied in 20 consecutive patients. Episodes of induced tachycardia that terminated spontaneously within the 1st minute after initiation were included. Tachycardias ending spontaneously were associated with a reproducible course of hypotension at the onset followed by blood pressure recovery above control levels and termination. Spontaneous termination of tachycardias occurred within the A-V node 18 to 45 seconds (mean +/- standard error of the mean 27.9 +/- 5.3) after their onset. In the supine position (0 degrees) 9 (45 percent) of 20 patients showed spontaneous termination in 36 (16 percent) of 219 episodes of tachycardia. In the head-dependent position (-20 degrees) only 1 (8 percent) of 13 patients manifested spontaneous termination in 2 (4 percent) of 54 episodes. In the head up position (+60 degrees) only 1 (6 percent) of 18 patients exhibited termination in 2 (2 percent) of 102 episodes. After partial cholinergic blockade with intravenous hyoscine butylbromide, 20 mg, or atropine, 0.6 mg, none of five patients showed spontaneous termination in 25 episodes. After beta adrenergic blockade with 10 mg of propranolol intravenously, none of 16 patients showed spontaneous termination in 87 episodes of tachycardia. We conclude that the initial hypotension during tachycardia evokes a sympathetic response that increases blood pressure and this increase in turn causes a rise in vagal tone that breaks the tachycardia.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001285:Atropine / Q000627:therapeutic use; D001794:Blood Pressure; D004558:Electric Stimulation / Q000009:adverse effects; D004562:Electrocardiography; D005260:Female; D006352:Heart Ventricles / Q000503:physiopathology*; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use; D011187:Posture; D011433:Propranolol / Q000627:therapeutic use; D012018:Reflex / Q000502:physiology*; D012601:Scopolamine / Q000627:therapeutic use; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology*
D000319:Adrenergic beta-Antagonists; D010276:Parasympatholytics; D001285:Atropine; D011433:Propranolol; D012601:Scopolamine